BWAY · BrainsWay Ltd. American Depositary Shares
View on chartInsiders & Stakes
| Yiftach Roth Chief Scientist | ▼ Sell | Open Market | 1,072,305 Shares held | 6/2/2026 | View profile |
| Gilad Moiseyev Chief Technology Officer | ▼ Sell | Open Market | 53,098 Shares held | 6/15/2026 | View profile |
| Rayten Michal Ety Mitrany Director | ▼ Sell | Open Market | 12,500 Shares held | 5/26/2026 | View profile |
Transaction History
| Gilad Moiseyev | ▼ Sell | Open Market | 5,000 | — | 6/15/2026 |
| Yiftach Roth | ▼ Sell | Open Market | 1,000 | — | 6/2/2026 |
| Yiftach Roth | ▼ Sell | Open Market | 2,000 | — | 6/2/2026 |
| Yiftach Roth | ▼ Sell | Open Market | 2,000 | — | 6/1/2026 |
| Yiftach Roth | ▼ Sell | Open Market | 2,000 | — | 6/1/2026 |
| Rayten Michal Ety Mitrany | ▼ Sell | Open Market | 7,980 | — | 5/26/2026 |
| Gilad Moiseyev | ▲ Buy | Option Exercise | 7,500 | — | 5/25/2026 |
| Gilad Moiseyev | ▼ Sell | Tax Withholding | 1,902 | — | 5/25/2026 |
| Rayten Michal Ety Mitrany | ▼ Sell | Open Market | 10,000 | — | 5/25/2026 |
| Rayten Michal Ety Mitrany | ▲ Buy | Option Exercise | 17,500 | — | 5/20/2026 |
| Rayten Michal Ety Mitrany | ▼ Sell | Tax Withholding | 6,080 | — | 5/20/2026 |
| Rayten Michal Ety Mitrany | ▲ Buy | Option Exercise | 10,000 | — | 5/19/2026 |
| Rayten Michal Ety Mitrany | ▼ Sell | Tax Withholding | 3,440 | — | 5/19/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
BrainsWay Reports Expansion of TMS Insurance Coverage
BrainsWay announced that favorable insurance coverage for its Accelerated Deep TMS technology has expanded to over 70 million covered lives. This development is relevant as it potentially broadens the patient base for the company's devices. The stock is currently trading near its 52-week low, with an RSI of 30.3 indicating oversold conditions.
BrainsWay Reports Expansion of TMS Insurance Coverage. BrainsWay announced that favorable insurance coverage for its Accelerated Deep TMS technology has expanded to over 70 million covered lives. This development is relevant as it potentially broadens the patient base for the company's devices. The stock is currently trading near its 52-week low, with an RSI of 30.3 indicating oversold conditions.